50 results on '"Marcom, P. K."'
Search Results
2. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study
3. Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer
4. Self-efficacy for coping with symptoms moderates the relationship between physical symptoms and well-being in breast cancer survivors taking adjuvant endocrine therapy
5. Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care
6. The impact of sharing results of a randomized breast cancer clinical trial with study participants
7. Abstract P3-08-10: Characterization of oncotype DX recurrence score and chemotherapy utilization patterns in young women (≤40) with early stage ER+/HER-, lymph node negative breast cancer
8. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
9. Detecting geriatric needs in older patients with breast cancer through use of a brief geriatric screening tool.
10. Higher symptom burden is associated with lower function in women taking adjuvant endocrine therapy for breast cancer.
11. Changes in Body Composition, Metabolic Rates, Energy Intake and Physical Activity in the Year after the Diagnosis of Breast Cancer. Comparing Patients Who Receive Adjuvant Chemotherapy with Those Who Receive Localized Treatment
12. Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy.
13. Quality appraisal of clinical validation studies for multigene prediction assays of chemotherapy response in early-stage breast cancer.
14. Outcomes in phase II trials of metastatic breast cancer: Where is the bar?
15. Symptom experiences and nonadherent medication-taking behaviors of breast cancer patients taking adjuvant hormone therapy.
16. ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer.
17. Utilization of genomic signatures for chemotherapy response in prospective clinical studies.
18. A randomized phase II trial evaluating the performance of genomic expression profiles to direct the use of preoperative chemotherapy for early-stage breast cancer.
19. Gene expression profile testing for breast cancer: Patterns and predictors of use and impact on chemotherapy.
20. Factors influencing use of genetic tests in clinical practice among U.S. oncologists.
21. Use of SPARC, EGFR, and VEGFR expression to predict response to nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab (B) chemotherapy in triple-negative metastatic breast cancer (TNMBC).
22. Implementation of genomic predictors of chemotherapy response for guiding preoperative therapy in a prospective breast cancer trial
23. The impact of sharing results of a randomized breast cancer clinical trial with study participants
24. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer
25. Genomic-based signatures of chemosensitivity and ER/HER2 status in biologic replicate breast cancer samples
26. Integration of clinico-pathologic variables, mRNA, and microRNA profiles represents an optimal strategy to predict sensitivity to chemotherapeutic agents in breast cancer
27. Molecular signatures characterize early stage breast cancer arising in young women and have prognostic and therapeutic implications independent of ER status
28. Trastuzumab and vinorelbine or taxane chemotherapy for HER2+ metastatic breast cancer: The TRAVIOTA study
29. Relationship between numeracy and breast cancer patients’ estimates of adjuvant treatment benefit
30. Study participants’ perceptions of the process and impact of receiving results of N9831
31. A phase II trial of letrozole and trastuzumab for ER and/or PgR and HER2 positive metastatic breast cancer: Final results
32. A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer
33. RARbeta P2 promoter methylation: Potential biomarker for use with breast Random Periareolar Fine Needle Aspiration in breast cancer risk assessment
34. Do Patients Participating in Clinical Trials Want to Know Study Results?
35. Rocky Mountain Spotted Fever Complicated by Gangrene: Report of Six Cases and Review
36. Sodium channel density in hypomyelinated brain increased by myelin basic protein gene deletion
37. Hypermethylation of the Breast Cancer-Associated Gene 1 Promoter Does Not Predict Cytologic Atypia or Correlate with Surrogate End Points of Breast Cancer Risk.
38. Invasive breast cancer: Clinical practice guidelines in oncology
39. Retrospective evaluation of precision of gene- expression-based signatures of prognosis and tumor biology in replicate surgical biospecimens from patients with breast cancer.
40. Thermochemoradiotherapy improves oxygenation in locally advanced breast cancer.
41. Tumor oxygenation during concurrent hyperthermia, taxol, and radiation therapy for locally advanced breast cancer
42. immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial.
43. Ki67 as a Predictive Marker of Response to Neoadjuvant Chemotherapy in Patients with Early-Stage Breast Cancer (ESBC): A Systematic Review and Evidence Summary.
44. A cross-platform comparison of genomic signatures and OncotypeDx score to discover potential prognostic/predictive genes and pathways.
45. The association between timing in adjuvant chemotherapy administration and overall survival for women with breast cancer within the National Comprehensive Cancer Network (NCCN).
46. TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.
47. The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial.
48. Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy.
49. Phase I study of Doxil and vinorelbine in metastatic breast cancer.
50. Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.